🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

ARS Pharmaceuticals, Inc.

SPRY Healthcare
$2.96 $-0.4 (-11.90%)
Market Cap: $297.56 M
Gurus Holding
4
Popularity Rank
#2547
% of Shares Held
1.31%
Net Activity (Q3 2026)
+$584,157.08

Guru Ownership Trend

Guru Analysis for ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals, Inc. (SPRY), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q3 2026, a total of 4 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $3.9 M.

Top institutional holders include Daniel Loeb and Renaissance Technologies (RenTech).

Institutional sentiment is currently Bullish. This is evidenced by a $584,157.08 net inflow during the quarter.

Recent activity highlights Cliff Asness who increased their stake by 173.1%.

Key Holders

Top 5 by Value

Top 5 by Conviction

Recent Activity Breakdown (Q3 2026)

+$1.02 M
Total Buy Value
New Buys 1
Additions 1
-$432,732
Total Sell Value
Reductions 0
Sold Out 1

Guru Consensus (Q3 2026)

Based on recent activity
Net Sellers
1
Net Buyers
2

FAQs for ARS Pharmaceuticals, Inc. (SPRY)

Major holders include Daniel Loeb ($4.31 M), Renaissance Technologies (RenTech) ($750,802), Cliff Asness ($419,851). According to the latest reported data, 4 tracked investment managers collectively hold approximately 1.32 M shares.

According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $584,157.08, with 2 managers increasing positions and 1 managers reducing holdings.

During the most recent reporting period, 0 managers trimmed their positions, while 1 fully exited SPRY. The total reported sell value was $432,732.

Yes, 1 managers opened new positions in SPRY, and 1 increased their existing holdings. The total reported buy value was $1.02 M.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.09% 1,000,000 $4.31 M Q3 2026
0.00% New Buy 174,200 $750,802 Q3 2026
0.00% Add 173.1% 97,413 $419,851 Q3 2026
0.00% 45,895 $197,807 Q3 2026
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form